Skip Navigation

Your Environment. Your Health.

Infliximab in Treatment-Refractory Juvenile Dermatomyositis

Principal Investigator:

Clarissa Pilkington, M.B.B.S.

Study Hypothesis:

Treatment refractory patients with juvenile dermatomyostiis would improve with infliximab therapy.

Study Design:

Open label

Types & Number of IIM Studied:

5 patients with juvenile dermatomyositis

Entry Criteria:

Severe or treatment resistant juvenile dermatomyositis despite treatment with at least 2 DMARD pharmacological therapies (including methotrexate) and use of intravenous methylprednisolone, and physiotherapy. Patients also had calcinosis.

IMACS Core Set Measures Included:

Physician Global Activity-VAS, Patient Global Activity-VAS, Muscle Strength Testing-MMT, Functional Assessment Tools-CMAS, CHAQ, Laboratory-Muscle Enzymes, Extramuscular Assessment-Extramuscular Global Activity, MD Assessment of Outcome

Primary Outcome:

Examined improvement in core set measures.

Secondary Outcome:

Calcinosis, joint range of motion, adverse event assessment

Key Trial Dates:

Completed

Funding Sources:

Supported by the Cathyl Hayes Research Foundation.

Publications:

Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis., Rheumatology(Oxford), 2008 Jun;47(6):877-80.[Abstract ]

Contact:

Clarissa Pilkington, M.B.B.S.
Juvenile Dermatomyositis Research Centre
Institute of Child Health
University College of London
London, UK
clarissa.pilkington@gosh.nhs.uk
Return to Studies in the Repository listing

Back to Top